within Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B03X_OtherAntianemicPreparations.B03XA03_MethoxyPolyethyleneGlycolEpoetinBeta;

model MethoxyPolyethyleneGlycolEpoetinBeta
  extends Pharmacolibrary.Drugs.ATC.B.B03XA03;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>B03XA03</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Methoxy polyethylene glycol-epoetin beta (commonly known as C.E.R.A.) is a long-acting erythropoiesis-stimulating agent (ESA) used to treat anemia associated with chronic kidney disease (CKD) in adult and pediatric patients. It is approved for intravenous and subcutaneous administration for the correction and maintenance of hemoglobin levels.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult patients with chronic kidney disease (both on dialysis and non-dialysis). Values are mostly population means from published sources.</p><h4>References</h4><ol><li><p>Fishbane, S, et al., &amp; Reigner, B (2007). Pharmacokinetic and pharmacodynamic properties of methoxy polyethylene glycol-epoetin beta are unaffected by the site of subcutaneous administration. <i>Journal of clinical pharmacology</i> 47(11) 1390–1397. DOI:<a href=\"https://doi.org/10.1177/0091270007307570\">10.1177/0091270007307570</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/17962427/\">https://pubmed.ncbi.nlm.nih.gov/17962427</a></p></li><li><p>Chanu, P, et al., &amp; Frey, N (2020). Model-based approach for methoxy polyethylene glycol-epoetin beta drug development in paediatric patients with anaemia of chronic kidney disease. <i>British journal of clinical pharmacology</i> 86(4) 801–811. DOI:<a href=\"https://doi.org/10.1111/bcp.14186\">10.1111/bcp.14186</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31770451/\">https://pubmed.ncbi.nlm.nih.gov/31770451</a></p></li><li><p>Chang, Y, et al., &amp; Catlin, DH (2011). Screen and confirmation of PEG-epoetin β in equine plasma. <i>Drug testing and analysis</i> 3(1) 68–73. DOI:<a href=\"https://doi.org/10.1002/dta.212\">10.1002/dta.212</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/21254454/\">https://pubmed.ncbi.nlm.nih.gov/21254454</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end MethoxyPolyethyleneGlycolEpoetinBeta;
